Kaiser Permanente-backed respiratory device provider Vapotherm floated at the bottom of its range but raised $56m in its initial public offering.

Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux-backed synthetic DNA producer Twist Bioscience floated at the bottom of its range.

GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

The Legend Capital-backed sacral neuromodulation device developer floated in the middle of its range while upping the number of shares in the IPO.

Novartis and Access Industries were among the investors that bought $37.5m of the shares, which the cell therapy developer issued at a downgraded price.

Sina invested $5m as online financing platform Pintec, which also counts Xiaomi as an investor, went public in a $44.3m initial public offering.

The Brazilian payment and commerce services provider floated above its range and raised an extra $100m from Ant Financial through a private placement.

Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.

Orphan disease drug developer PhaseBio Pharmaceuticals, which counts Johnson & Johnson, Astellas and AstraZeneca as investors, cut the price of its shares sharply pre-offering.

The Novo-backed surgical implant provider floated at the top of its range and increased the number of shares in the offering.